US vaccine maker to establish research and production facilities

Published: 2007-07-12 06:57:00

Updated: 2007-07-12 06:57:00

VGX Pharmaceutical Inc., a U.S pharmaceutical company, will invest $200 million in building its Asian regional headquarters in Korea, according to the Ministry of Health and Welfare on July 9.

VGX is a leading biopharmaceutical company with strong product candidates for the treatment of infect...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK